{"id":"https://openalex.org/W4379328517","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.tps1116","title":"UCLA B-13: A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, with or without fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HR-, HER2+ breast cancer.","display_name":"UCLA B-13: A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, with or without fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HR-, HER2+ breast cancer.","publication_year":2023,"publication_date":"2023-06-01","ids":{"openalex":"https://openalex.org/W4379328517","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.tps1116"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2023.41.16_suppl.tps1116","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.tps1116","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2023.41.16_suppl.tps1116","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088539775","display_name":"Nicholas Patrick McAndrew","orcid":"https://orcid.org/0000-0002-6799-5204","observed_orcids":["https://orcid.org/0000-0002-6799-5204"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicholas Patrick McAndrew","raw_affiliation_strings":["David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068059897","display_name":"Sara Alsterlind Hurvitz","orcid":"https://orcid.org/0000-0001-7808-7191","observed_orcids":["https://orcid.org/0000-0001-7808-7191"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara A. Hurvitz","raw_affiliation_strings":["David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047005057","display_name":"Merry L. Tetef","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Merry L. Tetef","raw_affiliation_strings":["David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010783560","display_name":"Christine Kivork","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christine Kivork","raw_affiliation_strings":["David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038786944","display_name":"Larissa Ikenouye","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Larissa Ikenouye","raw_affiliation_strings":["David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015491002","display_name":"Dennis J. Slamon","orcid":"https://orcid.org/0000-0002-6330-498X","observed_orcids":["https://orcid.org/0000-0002-6330-498X"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dennis J. Slamon","raw_affiliation_strings":["David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I161318765"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"41","issue":"16_suppl","first_page":"TPS1116","last_page":"TPS1116"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.8715999722480774,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.8715999722480774,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.11190000176429749,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.004100000020116568,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ribociclib","display_name":"ribociclib","score":0.7789999842643738},{"id":"https://openalex.org/keywords/tucatinib","display_name":"tucatinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9900000095367432},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9169999957084656},{"id":"https://openalex.org/keywords/neoadjuvant-therapy","display_name":"neoadjuvant therapy","score":0.9190000295639038},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.8379999995231628},{"id":"https://openalex.org/keywords/fulvestrant","display_name":"fulvestrant","score":0.953000009059906},{"id":"https://openalex.org/keywords/hormone-receptor-status","display_name":"hormone receptor status","score":0.5709999799728394},{"id":"https://openalex.org/keywords/chemotherapy-free-regimen","display_name":"chemotherapy-free regimen","score":0.5920000076293945},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5740000009536743},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.45500001311302185},{"id":"https://openalex.org/keywords/her2-low-breast-cancer","display_name":"HER2-low breast cancer","score":0.5550000071525574},{"id":"https://openalex.org/keywords/pertuzumab","display_name":"pertuzumab","score":0.6809999942779541},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.7720000147819519},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.9879999756813049}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.870084285736084},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.7026264667510986},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6854825019836426},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.6628348231315613},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6189113259315491},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.60919588804245},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5081071853637695},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.49909496307373047},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.49313896894454956},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4497798979282379},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.4248195290565491},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.41986769437789917}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2023.41.16_suppl.tps1116","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.tps1116","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2023.41.16_suppl.tps1116","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2623866550","https://openalex.org/W7162639705","https://openalex.org/W2803163286","https://openalex.org/W4246592373","https://openalex.org/W2941779371","https://openalex.org/W3088090224","https://openalex.org/W4281632287","https://openalex.org/W4206982757","https://openalex.org/W2789700352","https://openalex.org/W4220747915"],"abstract_inverted_index":{"TPS1116":[0],"Background:":[1],"Overexpression":[2],"of":[3,17,28,70,87,117,120,156,159,166,176,201,230,241,265,267,287,335],"the":[4,31,83,114,118,143,195,237,242,268,312],"HER2":[5],"protein":[6],"is":[7],"an":[8,68,124],"important":[9],"prognostic":[10],"and":[11,20,33,85,122,169,220,225,332],"predictive":[12,294],"biomarker":[13,330],"in":[14,30,97,133,209,236,258,293,304,311,326],"about":[15],"20%":[16],"breast":[18,104,138],"cancers,":[19],"while":[21],"trastuzumab-based":[22],"regimens":[23,37],"are":[24],"still":[25],"considered":[26],"standard":[27,57],"care":[29],"early":[32],"metastatic":[34,136],"settings,":[35],"these":[36],"require":[38],"chemotherapy":[39,90],"co-administration.":[40],"Pre-clinical":[41],"mouse":[42],"models":[43],"suggest":[44],"that":[45],"a":[46,174,228],"tucatinib/CDK":[47],"4/6":[48],"inhibitor":[49],"combination":[50,92,119],"regimen":[51],"may":[52],"be":[53,131,151,186,234,246,254,302,316],"equally":[54],"effective":[55],"as":[56],"regimens.":[58],"Thus,":[59],"finding":[60],"more":[61],"effective/tolerable":[62],"therapies":[63],"for":[64,173,291],"this":[65],"disease":[66],"remains":[67],"area":[69],"unmet":[71],"need.":[72],"This":[73],"randomized,":[74],"open":[75],"label,":[76],"phase":[77,127,145,182,238],"II":[78],"clinical":[79],"trial":[80,129,338],"will":[81,130,150,185,233,245,253,301,315],"explore":[82],"safety":[84,115],"efficacy":[86],"two":[88],"novel,":[89],"free":[91],"drug":[93],"regimens,":[94],"given":[95],"neoadjuvantly,":[96],"patients":[98,134,149,190,232],"with":[99,135,163],"anatomic":[100],"stage":[101],"I-III,":[102],"HER2+":[103,137],"cancer.":[105],"Methods:":[106],"Phase":[107,213],"1b":[108,128],"dose":[109,184,197,210],"escalation":[110],"trial:":[111,216],"To":[112,289],"establish":[113],"profile":[116],"ribociclib":[121,160],"tucatinib,":[123],"initial":[125],"dose-finding":[126],"performed":[132],"cancer":[139],"before":[140],"moving":[141],"into":[142],"larger":[144],"2":[146,183,214,239,319],"trial.":[147],"3-6":[148],"assigned":[152],"sequentially":[153],"to":[154,261],"groups":[155],"increasing":[157],"doses":[158,165],"(200mg-600":[161],"mg)":[162],"fixed":[164],"tucatinib":[167],"(300mg)":[168],"trastuzumab":[170],"(SOC":[171],"dosing)":[172],"total":[175,229],"four":[177],"28-day":[178],"cycles.":[179,320],"The":[180],"recommended":[181],"established":[187],"when":[188],"6":[189],"have":[191],"been":[192,207],"treated":[193],"at":[194],"highest":[196],"level":[198,211],"cohort.":[199],"As":[200],"January":[202],"2023,":[203],"1":[204,300],"participant":[205],"has":[206],"enrolled":[208,235],"1.":[212],"neoadjuvant":[215],"Following":[217],"MTD":[218],"determination":[219],"approval":[221],"from":[222],"regulatory":[223],"boards":[224],"funding":[226],"partners,":[227],"100":[231],"portion":[240],"study.":[243],"Enrollment":[244],"stratified":[247],"by":[248,283],"hormone":[249],"receptor":[250],"status.":[251],"Patients":[252],"randomized":[255],"1:1":[256],"(25":[257],"each":[259],"group)":[260],"receive":[262],"six":[263],"cycles":[264],"one":[266,284],"following":[269],"regimens:":[270],"ribociclib/trastuzumab/tucatinib/+/-":[271],"fulvestrant":[272],"(28":[273],"day":[274,280],"cycles)":[275],"or":[276],"docetaxel/carboplatin/trastuzumab/pertuzumab":[277],"(SOC,":[278],"21":[279],"cycles),":[281],"preceded":[282],"run-in":[285],"cycle":[286,299],"trastuzumab/pertuzumab.":[288],"assess":[290],"changes":[292,325],"molecular":[295],"biomarkers,":[296],"biopsies":[297],"pre-and-post":[298],"planned":[303,317],"all":[305],"arms.":[306],"Early":[307],"imaging":[308],"response":[309],"assessments":[310],"experimental":[313],"arms":[314],"after":[318],"Other":[321],"endpoints":[322],"include":[323],"safety,":[324],"Ki67":[327],"expression,":[328],"RCBi,":[329],"analysis,":[331],"health-related":[333],"quality":[334],"life.":[336],"Clinical":[337],"information:":[339],"NCT05319873":[340],".":[341]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-10T09:11:00.788812","created_date":"2023-06-05T00:00:00"}